Aberrant Wnt/β-catenin signalling is a well-established driver of desmoid tumour pathogenesis that may be effectively targeted via downstream blockade.

The role of growth factors in desmoid tumour pathogenesis is best appreciated through the clinical trial success of tyrosine kinase inhibitor drugs targeting such factors.

Oestrogen receptor expression data may only offer a superficial insight into oestrogen signalling mechanisms with clinical findings opposing anti-hormonal therapy, although further treatment opportunities exist within the tumour microenvironment.